DRG Epidemiology’s coverage of osteoarthritis (OA) pain comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets (the United States, France, Germany,…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…
The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe…
With an increasing prevalence due to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers and drug launches will…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e…
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP…
The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier…
The schizophrenia therapy market is very crowded. Many of the antipsychotic therapies are generic, although newer oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) are also…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
MARKET OUTLOOK QUESTIONS ANSWERED What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends in…